Medical Use
Nextstellis is the first and only FDA-approved oral contraceptive that combines drospirenone (a progestin) and estetrol (an estrogen) to prevent pregnancy. It is unique as the first oral contraceptive to contain E4, which is derived from a plant source and selectively acts on tissues. This helps support the health of the uterus, vagina, and bones while having minimal impact on the liver and breast tissue.
Note: Nextstellis may be less effective for women with a body mass index (BMI) of 30 or higher. Its safety and effectiveness in women with a BMI of 35 or higher are not known.
Recommended Dosage: Take one pill daily for 28 consecutive days: one pink active tablet for the first 24 days, followed by one white inactive tablet for the next four days. The tablets should be taken orally at the same time each day, with or without food.
If vomiting or severe diarrhea occurs within 3 to 4 hours after taking an active pill, take another active pill as soon as possible, ideally within 12 hours of the usual time. If more than two tablets are missed, follow the instructions for missed doses, which may include using a backup non-hormonal contraceptive method.
Warning & Precautions
Before starting treatment with drospirenone and estetrol, it is important to review any personal or family history of thromboembolic or thrombotic disorders. Women at higher risk for arterial or venous thrombotic or thromboembolic diseases should not use this medication.
Nextstellis 3 mg/14.2 mg is not recommended for women with uncontrolled hypertension or hypertension with vascular complications. Blood pressure should be monitored regularly in all women, including those with well-controlled hypertension, and treatment should be discontinued if there is a significant increase in blood pressure.
Migraines with aura are a contraindication for using this medication. If a woman develops recurrent, persistent, or severe migraines while taking Nextstellis, the treatment should be stopped. Additionally, if the severity and frequency of migraines increase during the use of combined hormonal contraceptives (CHC), the medication should be discontinued.
Nextstellis is not suitable for women with current or past hormonally-sensitive cancers, such as breast cancer. If a hormonally-sensitive malignancy is diagnosed, treatment should be stopped immediately, as this medication may promote the growth of hormone receptor-positive tumors both within and outside the reproductive tract.
Women with acute hepatitis or severe (decompensated) cirrhosis should avoid using Nextstellis. Treatment should be paused or permanently discontinued if there is a persistent or significant elevation of liver enzymes, as this medication can cause elevated liver enzyme levels.
Unscheduled bleeding and spotting may occur in women taking Nextstellis, especially during the first four months of treatment. These irregularities may resolve over time or with a change to another contraceptive. If bleeding persists or occurs after previously regular cycles, further evaluation for causes such as pregnancy or malignancy is necessary.
Documentation Availability
Documents required to import NEXTSTELLIS to India?
NEXTSTELLIS (Drospirenone and Estetrol) Tablets can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:
- (i)2 ID proofs along with PAN card details along with attested scanned copies
- (ii)Valid doctor prescription scanned copy
- (iii)Doctor’s MCI number
- (iv)Doctor’s mobile number
- (v)Patients diagnostic reports
How is the order confirmed?
The order will be confirmed only after the receipt of:
- (i)The above-mentioned documents and drug availability.
- (ii)Import permit if applicable.
Sourcing & Delivery
The Rx4U team has extensive experience in sourcing NEXTSTELLIS (Cancer Treatment Medicines) from around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.
FAQ
What is the Generic Name for Nextstellis®?
The generic name for Nextstellis® is Drospirenone and Estetrol.
Who manufactures Nextstellis®?
Nextstellis® is manufactured by Mayne Pharma US.
Is Nextstellis® FDA approved?
Yes, Nextstellis® was approved by the FDA on April 15, 2021.
What are the available dosages and forms of Nextstellis®?
Nextstellis® is available as a pack of 28 tablets for oral use, which includes:
- 24 pink active tablets, each containing 3 mg drospirenone and 14.2 mg estetrol
- 4 white inactive tablets
Where can I find the best price for Nextstellis® in India?
For the best price on Nextstellis in India, contact the Rx4u team.
What are the common side effects of Nextstellis®?
Common side effects include mood disturbances, headaches, irregular bleeding, acne, breast symptoms, dysmenorrhea, decreased libido, and weight gain.
How much does Nextstellis cost in India?
Yes, you can safely purchase Nextstellis online in India through https://rx4u.in/.
*Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.
